BP Drug Flops in Heart Failure (CME/CE)

(MedPage Today) -- The blood pressure drug aliskiren (Tekturna) doesn't help prevent rehospitalization or death for heart failure patients, the ASTRONAUT trial showed.
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news

Related Links:

Publication date: Available online 5 April 2020Source: Urology Case ReportsAuthor(s): Arvind Krishnan, Jeffy Jacob, Trushar Patel
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research
Authors: Lin X, Fang L Abstract Heart failure (HF) is defined as a clinical syndrome resulting from structural or functional impairment of ventricular fillings or ejections of blood. Currently, HF is divided into three groups which include HF with reduced ejection fraction (HFrEF), HF with preserved ejection fraction (HFpEF) and HF with midrange EF (HFmrEF). Even though major advances have been made in treating HFrEF during the past decades, heart failure is a fatal disease. In this review, we briefly summarize the current advances in pharmaceutical managements for heart failure, which includes drugs used in acute ...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Authors: Gu D, Qu J, Zhang H, Zheng Z Abstract Coronary revascularization is the most important strategy for coronary artery disease. This review summarizes the current most prevalent approaches for coronary revascularization and discusses the evidence on the mechanisms, indications, techniques, and outcomes of these approaches. Targeting coronary thrombus, fibrinolysis is indicated for patients with diagnosed myocardial infarction and without high risk of severe hemorrhage. The development of fibrinolytic agents has improved the outcomes of ST-elevation myocardial infarction. Percutaneous coronary intervention has...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Myocardial calcifications are often discovered incidentally and result from dystrophic or metastatic deposition of calcium1. Dystrophic calcification represents the sequalae of local tissue damage with necrosis, most commonly from myocardial ischemia. Unlike the prior, metastatic calcification is the result of abnormal calcium homeostasis; including renal failure, hyperparathyroidism, and vitamin D deficiency. Myocardial calcifications are not entirely a benign finding, since they can lead to heart failure, arrhythmias and sudden cardiac death2.
Source: The American Journal of Medicine - Category: General Medicine Authors: Tags: Clinical Communication to the Editor Source Type: research
Elucidation of the biologic mechanisms underlying the pathogenesis of transthyretin (TTR) amyloidosis has led to the approval of therapies to treat both inherited (hATTR) and age-related or wild-type (wtATTR) forms of transthyretin amyloidosis manifesting as neuropathy and/or cardiomyopathy1-3. These developments have been hailed as a model of scientific and medical progress emanating from precision medicine, which can arrest or slow progression of fatal disorders and provide a potential pathway for progress in other complex clinical syndromes such as heart failure with preserved ejection fraction by endo-phenotyping.
Source: The American Journal of Medicine - Category: General Medicine Authors: Tags: Commentary Source Type: research
The current SARS-CoV-2 pandemic has high fatality rates and imposes increasingly severe social and economic impacts worldwide. Covid-19 patients with cardiovascular disease are at increased risk of death. They are very often treated with drugs targeting the renin-angiotensin-aldosterone system, where angiotensin converting enzyme (ACE) is of particularly importance. Angiotensin converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARBs) are standard therapies for high blood pressure and heart failure (HF) and currently prescribed to more than 25 Mio people in Germany alone (approx.
Source: Journal of Molecular and Cellular Cardiology - Category: Cytology Authors: Tags: Letter to the editor Source Type: research
This report reviews our basic studies and clinical trials using curcumin therapeutically to prevent heart failure, as well as the possibility of clinical applications of curcumin. PMID: 32238626 [PubMed - in process]
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - Category: Drugs & Pharmacology Authors: Tags: Yakugaku Zasshi Source Type: research
Publication date: Available online 2 April 2020Source: Revista Clínica Española (English Edition)Author(s): J.P. Miramontes González, L. Pérez de Isla
Source: Revista Clinica Espanola - Category: Internal Medicine Source Type: research
PMID: 32238128 [PubMed - as supplied by publisher]
Source: Current Topics in Medicinal Chemistry - Category: Chemistry Authors: Tags: Curr Top Med Chem Source Type: research
Resumo A s índrome da fístula artério-portal (FAP) é uma rara e reversível causa de hipertensão portal pré-sinusoidal, ocasionada pela comunicação de uma artéria visceral com o sistema venoso portal. A maioria dos pacientes é assintomática, mas quando desenvolvem sintomas, estes são mais relaciona dos com sangramento gastrointestinal, ascite, insuficiência cardíaca congestiva e diarreia. Este desafio terapêutico apresenta um caso de FAP decorrente de ferimento antigo por arma branca e subsequente evoluç&atil...
Source: Jornal Vascular Brasileiro - Category: Surgery Source Type: research
More News: Cardiology | Cardiovascular | Heart | Heart Failure | Tekturna